Exchange: NASDAQ·Updated 11:21 AM EDT
AMRX logo

AMRXAmneal Pharmaceuticals Inc - Ordinary Shares - Class A

$16.91
$0.27
(1.57%)
Today
EarningsJul 30
Mkt Cap$5.49B
Vol210,839.00
News
all
press releases
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
More News
News Placeholder
Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
News Placeholder
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
News Placeholder
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Zacks
News Placeholder
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
News Placeholder
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire NASHVILLE, Tenn., June 10, 2026 Amneal's Commitment Helps Support a Reliable Supply of Essential...
PR Newswire
News Placeholder
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.
Zacks
News Placeholder
Is Amneal a Buy Before Rytary Generic Erosion?
AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.
Zacks
News Placeholder
What's Driving Amneal's 2026 Growth Outlook?
AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.
Zacks
News Placeholder
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
<
1
2
...
>

Advertisement|Remove ads.